WO2001066551A8 - Azole compounds as therapeutic agents for fungal infections - Google Patents

Azole compounds as therapeutic agents for fungal infections

Info

Publication number
WO2001066551A8
WO2001066551A8 PCT/IB2001/000300 IB0100300W WO0166551A8 WO 2001066551 A8 WO2001066551 A8 WO 2001066551A8 IB 0100300 W IB0100300 W IB 0100300W WO 0166551 A8 WO0166551 A8 WO 0166551A8
Authority
WO
WIPO (PCT)
Prior art keywords
fungal infections
therapeutic agents
azole compounds
compounds
relates
Prior art date
Application number
PCT/IB2001/000300
Other languages
French (fr)
Other versions
WO2001066551A2 (en
WO2001066551A3 (en
Inventor
Ashwani Kumar Verma
Sudershan K Arora
Jasbir Singh Arora
Ashok Rattan
Original Assignee
Ranbaxy Lab Ltd
Ashwani Kumar Verma
Sudershan K Arora
Jasbir Singh Arora
Ashok Rattan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN198DE2000 external-priority patent/IN191188B/en
Application filed by Ranbaxy Lab Ltd, Ashwani Kumar Verma, Sudershan K Arora, Jasbir Singh Arora, Ashok Rattan filed Critical Ranbaxy Lab Ltd
Priority to PL01365072A priority Critical patent/PL365072A1/en
Priority to AU34023/01A priority patent/AU3402301A/en
Priority to NZ521241A priority patent/NZ521241A/en
Priority to CA002402345A priority patent/CA2402345A1/en
Priority to JP2001565367A priority patent/JP2004501867A/en
Priority to EP01906061A priority patent/EP1278755A2/en
Publication of WO2001066551A2 publication Critical patent/WO2001066551A2/en
Publication of WO2001066551A3 publication Critical patent/WO2001066551A3/en
Publication of WO2001066551A8 publication Critical patent/WO2001066551A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.
PCT/IB2001/000300 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections WO2001066551A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL01365072A PL365072A1 (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections
AU34023/01A AU3402301A (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections
NZ521241A NZ521241A (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections
CA002402345A CA2402345A1 (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections
JP2001565367A JP2004501867A (en) 2000-03-07 2001-03-01 Azole compounds as therapeutics for fungal infections
EP01906061A EP1278755A2 (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN198DE2000 IN191188B (en) 2000-03-07 2000-03-07
IN198/DEL/2000 2000-03-07
US09/575,578 US6670363B1 (en) 2000-03-07 2000-05-22 Azole compounds as therapeutic agents for fungal infections
US09/575,578 2000-05-22

Publications (3)

Publication Number Publication Date
WO2001066551A2 WO2001066551A2 (en) 2001-09-13
WO2001066551A3 WO2001066551A3 (en) 2002-03-07
WO2001066551A8 true WO2001066551A8 (en) 2003-06-26

Family

ID=26324879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000300 WO2001066551A2 (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections

Country Status (8)

Country Link
EP (1) EP1278755A2 (en)
JP (1) JP2004501867A (en)
AU (1) AU3402301A (en)
CA (1) CA2402345A1 (en)
NZ (1) NZ521241A (en)
PL (1) PL365072A1 (en)
RU (1) RU2002126272A (en)
WO (1) WO2001066551A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218505A1 (en) * 2000-11-30 2002-06-11 Senju Pharmaceutical Co. Ltd. Pancreatitis remedies and medicines for prevention and therapy of reflux esophagitis
MXPA03005899A (en) 2000-12-26 2004-01-26 Ranbaxy Lab Ltd Azole compounds as anti-fungals agents.
EP1356816B1 (en) 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
IN192526B (en) * 2001-09-25 2004-04-24 Ranbaxy Lab
AU2002328176A1 (en) * 2002-08-26 2004-03-11 Ranbaxy Laboratories Limited Azole derivatives as antifungal agents
EP1413301A1 (en) * 2002-10-24 2004-04-28 Bayer CropScience SA Antifungal medicaments comprising arylamidine derivatives
WO2007020888A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent, and therapeutic agent for sleep disorder
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
EA032840B8 (en) 2011-06-22 2020-06-18 Вайоми Терапеутикс Лимитед Conjugate-based antifungal prodrugs and use thereof
CN102617494B (en) * 2012-03-15 2014-10-29 南京工业大学 Triazole compounds containing olefine ether structure, and preparation method and application thereof
MX2015016675A (en) 2013-06-04 2016-07-15 Vyome Biosciences Pvt Ltd Coated particles and compositions comprising same.
US10071103B2 (en) 2014-01-29 2018-09-11 Vyome Biosciennces Pvt. Ltd. Treatments for resistant acne
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2018060070A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW218017B (en) * 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
CA2134417A1 (en) * 1993-12-22 1995-06-23 Katsumi Itoh Optically active azole derivatives, their production and use
US5639754A (en) * 1994-07-12 1997-06-17 Janssen Pharmaceutica N.V. Urea and thiourea derivatives of azolones
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals

Also Published As

Publication number Publication date
EP1278755A2 (en) 2003-01-29
RU2002126272A (en) 2004-08-10
WO2001066551A2 (en) 2001-09-13
WO2001066551A3 (en) 2002-03-07
NZ521241A (en) 2004-02-27
PL365072A1 (en) 2004-12-27
CA2402345A1 (en) 2001-09-13
JP2004501867A (en) 2004-01-22
AU3402301A (en) 2001-09-17

Similar Documents

Publication Publication Date Title
WO2001066551A3 (en) Azole compounds as therapeutic agents for fungal infections
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004005286A3 (en) Viral inhibitors
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2004058769A3 (en) Triazolopyridazines as protein kinases inhibitors
ATE245148T1 (en) 5-ARYL-1H-1,2,4 TRIAZOLE COMPOUNDS AS CYCLOOXYGENASE -2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
WO2004016086A3 (en) 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
NZ315184A (en) Use of fluconazole for inhibiting the growth of cancers and viral infections
WO2002070464A3 (en) Hydrazones and their therapeutic use
MXPA02011039A (en) Fungicidal combinations of active agents.
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
WO2003086271A3 (en) Azole derivatives as antifungal agents
WO2002036203A3 (en) Azole containing compositions with enhanced antifungal activity
WO2002085358A3 (en) Antiviral agents and methods of treating viral infections
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases
PT1427417E (en) 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2003051838A3 (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2001 565367

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001906061

Country of ref document: EP

Ref document number: 2402345

Country of ref document: CA

Ref document number: 521241

Country of ref document: NZ

Ref document number: 34023/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2002 2002126272

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2001906061

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 37/2001 UNDER (71) THE ADDRESS OF "RANBAXY LABORATORIES LIMITED" CORRECTED; UNDER (72, 75) THE ADDRESSES OF "VERMA, ASHWANI, KUMAR", "ARORA, JASBIR, SINGH" AND "RATTAN, ASHOK" CORRECTED

WWP Wipo information: published in national office

Ref document number: 521241

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521241

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001906061

Country of ref document: EP